Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ProQR ( (PRQR) ) has shared an announcement.
On August 7, 2025, ProQR Therapeutics N.V. announced its financial results for the second quarter of 2025, ending June 30. The company reported a decrease in revenue compared to the previous year, alongside increased research and development costs, leading to a significant operating loss. This financial performance may impact ProQR’s market positioning and stakeholder confidence as the company navigates the challenges of developing treatments for rare genetic disorders.
The most recent analyst rating on (PRQR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
The overall stock score for ProQR is primarily influenced by its financial performance, which shows strong revenue growth but significant challenges in profitability and cash flow management. Technical analysis indicates a neutral trend with potential for slight upward momentum. However, the valuation is weak due to a negative P/E ratio and lack of dividend yield. These factors combined result in a moderate overall score.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V. operates in the biotechnology industry, focusing on the development of RNA therapies for the treatment of genetic disorders. The company is primarily engaged in creating innovative treatments for rare diseases, with a market focus on genetic eye disorders.
Average Trading Volume: 299,583
Technical Sentiment Signal: Hold
Current Market Cap: $222.5M
Find detailed analytics on PRQR stock on TipRanks’ Stock Analysis page.